← Back to Search

Dietary Supplement

Testosterone for Aging (GRAMS Trial)

Phase 1
Waitlist Available
Research Sponsored by The University of Texas Medical Branch, Galveston
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 30 days post-discharge
Awards & highlights

Summary

This trial will study how well two different interventions help older adults recover from a hospital stay.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~30 days post-discharge
This trial's timeline: 3 weeks for screening, Varies for treatment, and 30 days post-discharge for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Physical Performance
Secondary study objectives
30 day re-admission
Handgrip Strength
Physical Activity Level

Trial Design

4Treatment groups
Experimental Treatment
Placebo Group
Group I: TestosteroneExperimental Treatment2 Interventions
Placebo Supplement Testosterone Injection
Group II: Protein Supplement + TestosteroneExperimental Treatment2 Interventions
Protein Supplement Testosterone Injection
Group III: Protein SupplementExperimental Treatment2 Interventions
Protein Supplement Placebo Injection
Group IV: PlaceboPlacebo Group2 Interventions
Placebo Supplement Placebo Injection
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Testosterone
2009
Completed Phase 4
~2020
Protein Supplement
2009
Completed Phase 3
~5380

Find a Location

Who is running the clinical trial?

The University of Texas Medical Branch, GalvestonLead Sponsor
248 Previous Clinical Trials
56,754 Total Patients Enrolled
10 Trials studying Aging
798 Patients Enrolled for Aging
Elena Volpi, MD, PhDStudy ChairUTMB
6 Previous Clinical Trials
2,732 Total Patients Enrolled
3 Trials studying Aging
368 Patients Enrolled for Aging

Media Library

Protein Supplement (Dietary Supplement) Clinical Trial Eligibility Overview. Trial Name: NCT02990533 — Phase 1
Aging Research Study Groups: Placebo, Testosterone, Protein Supplement, Protein Supplement + Testosterone
Aging Clinical Trial 2023: Protein Supplement Highlights & Side Effects. Trial Name: NCT02990533 — Phase 1
Protein Supplement (Dietary Supplement) 2023 Treatment Timeline for Medical Study. Trial Name: NCT02990533 — Phase 1
~9 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top